The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Bone Loss and Fracture Risk Associated with Cancer Therapy
Open accessAbstract
Learning Objectives: After completing this course, the reader will be able to: Identify cancer therapies associated with bone loss.Explain the unique aspects of cancer therapy–associated bone loss.Screen for and manage bone loss in cancer patients.Describe the safety profile of bisphosphonate drug treatment. Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com Background. Cancer patients experience osteoporosis resulting from accelerated loss of bone mineral density (BMD) caused by their treatment. Such bone loss greatly increases the risk for fracture and can have other serious effects on quality of life. Methods. In the current report, the author focuses on studies of cancer therapy-associated bone loss, its prevalence and pathogenesis, and resulting clinical impact. Options for management and prevention are also reviewed, including treatment guidelines where available. Results. A variety of cancer therapies, including hormonal therapy, chemotherapy, and glucocorticoids, affect gonadal hormone production, which increases bone resorption and decreases BMD. Such bone loss occurs more rapidly and to a greater degree than normal age-related osteoporosis, increases the risk for fracture and other morbidities, and decreases survival. Regular BMD screening and early intervention can prevent further decline in bone density and bone quality. Pharmacologic therapy with oral and i.v. bisphosphonates has been shown to slow bone loss in patients receiving cancer therapy, and the i.v. bisphosphonate zoledronic acid can increase BMD in patients with cancer treatment-related bone loss. Lifestyle changes, including supplementation with calcium and vitamin D, diet, and proper exercise, can also slow the rate of bone loss. Conclusions. Bone loss associated with various cancer therapies significantly affects bone health. Early initiation of bisphosphonates, when indicated, and lifestyle modification can improve patient outcomes. Education of patients and health care professionals regarding the importance of this complication and effective treatment options is essential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Holick, M. F. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.6.1678s · Cited by 3,198
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Chesnut, C. H., Skag, A., Christiansen, C., Recker, R., Stakkestad, J. A., Hoiseth, A., Felsenberg, D., Huss, H., Gilbride, J., Schimmer, R. C., et al. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.040325 · Cited by 1,229
Miller, P. D., Mcclung, M. R., Macovei, L., Stakkestad, J. A., Luckey, M., Bonvoisin, B., Reginster, J.-Y., Recker, R. R., Hughes, C., Lewiecki, E. M., et al. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.050313 · Cited by 333
Perez, E. A., Josse, R. G., Pritchard, K. I., Ingle, J. N., Martino, S., Findlay, B. P., Shenkier, T. N., Tozer, R. G., Palmer, M. J., Shepherd, L. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4882 · Cited by 307
Safety of intravenous and oral bisphosphonates and compliance with dosing regimens
Conte, P., & Guarneri, V. (2004) · The Oncologist · doi:10.1634/theoncologist.9-90004-28 · Cited by 241 · cited 4×
“Given the potential for renal toxicity, monitoring of serum creatinine levels is recommended at baseline and prior to drug infusions [30, 48 ].”
BackgroundInfluential
Cited by
Poly(lactic-co-glycolic acid)-based composite bone-substitute materials
Zhao, D., Zhu, T., Li, J., Cui, L., Zhang, Z., Zhuang, X., & Ding, J. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.08.016 · Cited by 387
Management of common clinical problems experienced by survivors of cancer
Emery, J., Butow, P., Lai-Kwon, J., Nekhlyudov, L., Rynderman, M., & Jefford, M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00242-2 · Cited by 326
Hadji, P., Aapro, M. S., Body, J.-J., Gnant, M., Brandi, M. L., Reginster, J. Y., Zillikens, M. C., Glüer, C.-C., de Villiers, T., Baber, R., et al. (2017) · Journal of Bone Oncology · doi:10.1016/j.jbo.2017.03.001 · Cited by 277
Dunn, L. K., Mohammad, K. S., Fournier, P. G. J., McKenna, C. R., Davis, H. W., Niewolna, M., Peng, X. H., Chirgwin, J. M., & Guise, T. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006896 · Cited by 212
Self-citationTherapy-Induced Senescence Drives Bone Loss
Yao, Z., Murali, B., Ren, Q., Luo, X., Faget, D. V., Cole, T., Ricci, B., Thotala, D., Monahan, J., van Deursen, J. M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2348 · Cited by 129
Metadata
- Authors
- Guise, T. A.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-11-01
- Volume
- 11
- Issue
- 10
- Pages
- 1121-1131
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2156938611
- Cited by
- 239
- References
- 7
- FWCI
- 4.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bone Loss and Fracture Risk Associated with Cancer Therapy. https://app.cochat.ai/papers/10.1634/theoncologist.11-10-1121
- The paper
- Guise, T. A. (2006). Bone Loss and Fracture Risk Associated with Cancer Therapy. The Oncologist. https://doi.org/10.1634/theoncologist.11-10-1121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.